Papillary endothelial hyperplasia (Masson's tumor) of the breast: A diagnostic challenge.

Papillary endothelial hyperplasia (PEH) or Masson's tumor is a rare benign vascular tumor that usually appears in the soft tissues of the head and neck, trunk and extremities, being extremely rare in the breast. Its diagnosis can be a challenge, especially in the follow-up of patients with previous disease of breast carcinoma. We present the case of a 65-year-old patient, with a history of bilateral breast cancer and reconstruction with implants, who presented a Masson's tumor during follow-up. An ultrasound scan was performed, showing a well-circumscribed mass in the left breast, located in the posterior contour of the implant. Subsequently, magnetic resonance imaging (MR) depicted an enhancing tumor, without infiltration of adjacent structures. Finally, the definitive anatomopathological diagnosis was obtained after surgical excision.

Valor del protocolo abreviado de resonancia magnética mamaria en el cribado de pacientes de alto riesgo / Value of an abbreviated protocol of breast magnetic resonance imaging for screening high-risk patients

OBJETIVO: Valorar la utilidad de los protocolos abreviados de resonancia magnética (RM) mamaria en el cribado de cáncer de mama en pacientes de alto riesgo, en comparación con el protocolo completo, y determinar la precisión diagnóstica en la caracterización de las lesiones mamarias de ambos protocolos. MATERIAL Y MÉTODOS: Se revisaron retrospectivamente 157 estudios de RM mamaria de 82 pacientes de alto riesgo realizadas en nuestro centro, desde enero de 2011 hasta enero de 2017. Se analizaron parámetros clínicos, radiológicos y anatomopatológicos. Se realizó la lectura de los diferentes protocolos: MIP, abreviado y completo por un radiólogo experto. Posteriormente se hizo un análisis estadístico. RESULTADOS: Se identificaron un total de 12 lesiones clasificadas en categoría BI-RADS 4 y 5 que fueron biopsiadas, de las cuales 11 resultaron ser malignas (91,67%) y 1 benigna (8,33%). Las lesiones malignas fueron: 4 carcinomas ductales in situ (33,33%) y 7 carcinomas ductales infiltrantes (58,33%). Todas las lesiones fueron detectadas con los tres protocolos y no se encontraron diferencias significativas entre sus respectivas áreas bajo la curva (p = 0,0650). CONCLUSIONES: En nuestro estudio no existen diferencias significativas entre los distintos protocolos (MIP, abreviado y completo). El protocolo abreviado se perfila como una herramienta prometedora en el cribado de cáncer de mama en pacientes de alto riesgo

OBJECTIVE: Value the utility of breast MRI abbreviated protocols for the screening of breast cancer in high-risk patients compared to the full protocol. METHODS: We performed a retrospective review of 157 breast MRI of 82 high-risk patients practiced in our hospital between January 2011 and January 2017. Clinical, radiological and anatomopathological parameters were analyzed. Reading of the different protocols (MIP, abbreviated and full) was made by an expert radiologist. Subsequent statistical analysis was done. RESULTS: A total amount of 12 findings classified as BI-RADS 4 and 5 were identified and performed a biopsy, resulting 11 of them to be malignant (91.67%) and 1 benign (8.33%). The malignant wounds included 4 intraductal carcinoma (33.33%) and 7 infiltrating ductal carcinoma (58.33%). All injuries were detected with the three protocols and no significant differences were found between their respective area under the ROC curve (p = 0.0650). CONCLUSIONS: In our study there are no significant differences between the different protocols (MIP, abbreviated and full), which places the abbreviated protocol as a promising tool for breast cancer screening in high-risk patients

Value of an abbreviated protocol of breast magnetic resonance imaging for screening high-risk patients. / Valor del protocolo abreviado de resonancia magnética mamaria en el cribado de pacientes de alto riesgo.

OBJECTIVE: Value the utility of breast MRI abbreviated protocols for the screening of breast cancer in high-risk patients compared to the full protocol. METHODS: We performed a retrospective review of 157 breast MRI of 82 high-risk patients practiced in our hospital between January 2011 and January 2017. Clinical, radiological and anatomopathological parameters were analyzed. Reading of the different protocols (MIP, abbreviated and full) was made by an expert radiologist. Subsequent statistical analysis was done. RESULTS: A total amount of 12 findings classified as BI-RADS 4 and 5 were identified and performed a biopsy, resulting 11 of them to be malignant (91.67%) and 1 benign (8.33%). The malignant wounds included 4 intraductal carcinoma (33.33%) and 7 infiltrating ductal carcinoma (58.33%). All injuries were detected with the three protocols and no significant differences were found between their respective area under the ROC curve (p=0.0650). CONCLUSIONS: In our study there are no significant differences between the different protocols (MIP, abbreviated and full), which places the abbreviated protocol as a promising tool for breast cancer screening in high-risk patients.

Valoración de los factores pronósticos radiopatológicos del cáncer de mama triple negativo y análisis del carcinoma in situ como factor pronóstico / Imaging and histologic prognostic factors in triple-negative breast cancer and carcinoma in situ as a prognostic factor

Objetivos. Analizar qué factores valorados en resonancia magnética (RM) y anatomopatológicos de los tumores triple negativo (TN) se relacionan con la recidiva tumoral y con una menor supervivencia libre de enfermedad. Valorar la supervivencia y las recidivas en función de la presencia de componente in situ (CIS). Material y métodos. Estudio retrospectivo de las RM realizadas desde 2007 a 2014, con inclusión de 122 mujeres con cáncer de mama TN y RM de estadificación. En RM se valoraron las características morfológicas (tamaño, márgenes, morfología y señal interna en secuencia T2) y dinámicas (perfusión y difusión). Se estudiaron también los factores anatomopatológicos (Ki67, p53, CK5/6, grado nuclear y Scarff-Bloom) y se analizó la presencia de CIS y el grado tumoral (alto o no alto grado). Se compararon las distintas variables con la presencia de recidiva y se realizó estudio de supervivencia. Resultados. El realce no nodular presentó mayor porcentaje en el grupo de recidivas, y la diferencia fue estadísticamente significativa (p=0,038) y se relacionó con una menor supervivencia libre de enfermedad (p=0,023). La restricción a la difusión (p=0,079) y el ki67 (p=0,052) no asociaron un peor pronóstico. Se detectó CIS en el 44% de los TN, con mayor proporción en el grupo de recidiva, sin relación con una menor supervivencia (p = 0,185). Conclusión. El realce no nodular demostró ser un factor de peor pronóstico. La restricción a la difusión, el ki67 y la presencia de CIS no se asociaron a una menor supervivencia libre de enfermedad (AU)

Objectives. To analyze what factors in magnetic resonance imaging (MRI) and histological study of triple-negative breast cancers are related to tumor recurrence and to shorter disease-free survival. To analyze survival and recurrence in function of the presence of an in situ component. Material and methods. This was a retrospective study of MRI staging examinations in 122 women with triple-negative breast cancer done from 2007 through 2014. In the MRI, we evaluated morphological variables (size, margins, morphology, internal signal in T2-weighted sequences) and dynamic variables (perfusion and diffusion). In the histological study, we evaluated Ki67, p53, CK5/6, nuclear grade, and Scarff-Bloom grade, as well as the presence of an in situ component and tumor grade (high grade or not high grade). We compared the variables between patients with tumor recurrence and those without, and we conducted a survival analysis. Results. Non-nodular enhancement was more common in patients with tumor recurrence (p=0.038) and was associated with shorter disease-free survival (p=0.023). Neither diffusion restriction (p=0.079) nor ki67 (p=0.052) was associated with a worse prognosis. An in situ component was detected in 44% of triple-negative tumors, and a greater proportion of patients in the group with tumor recurrence had an in situ component; however, the presence of an in situ component was not associated with shorter survival (p = 0.185). Conclusion. Non-nodular enhancement was associated with a worse prognosis. Diffusion restriction, ki67, and the presence of an in situ component were not associated with shorter disease-free survival (AU)

Imaging and histologic prognostic factors in triple-negative breast cancer and carcinoma in situ as a prognostic factor. / Valoración de los factores pronósticos radiopatológicos del cáncer de mama triple negativo y análisis del carcinoma in situ como factor pronóstico.

OBJECTIVES: To analyze what factors in magnetic resonance imaging (MRI) and histological study of triple-negative breast cancers are related to tumor recurrence and to shorter disease-free survival. To analyze survival and recurrence in function of the presence of an in situ component. MATERIAL AND METHODS: This was a retrospective study of MRI staging examinations in 122 women with triple-negative breast cancer done from 2007 through 2014. In the MRI, we evaluated morphological variables (size, margins, morphology, internal signal in T2-weighted sequences) and dynamic variables (perfusion and diffusion). In the histological study, we evaluated Ki67, p53, CK5/6, nuclear grade, and Scarff-Bloom grade, as well as the presence of an in situ component and tumor grade (high grade or not high grade). We compared the variables between patients with tumor recurrence and those without, and we conducted a survival analysis. RESULTS: Non-nodular enhancement was more common in patients with tumor recurrence (p=0.038) and was associated with shorter disease-free survival (p=0.023). Neither diffusion restriction (p=0.079) nor ki67 (p=0.052) was associated with a worse prognosis. An in situ component was detected in 44% of triple-negative tumors, and a greater proportion of patients in the group with tumor recurrence had an in situ component; however, the presence of an in situ component was not associated with shorter survival (p = 0.185). CONCLUSION: Non-nodular enhancement was associated with a worse prognosis. Diffusion restriction, ki67, and the presence of an in situ component were not associated with shorter disease-free survival.

Resonancia magnética en el cáncer de mama tratado con neoadyuvancia: correlación radiopatológica de la respuesta y supervivencia libre de enfermedad en función del subtipo molecular / Magnetic resonance imaging in breast cancer treated with neoadjuvant chemotherapy: Radiologic-pathologic correlation of the response and disease-free survival depending on molecular subtype

Objetivos. Valorar la respuesta radiológica, patológica y su correlación en los subtipos moleculares del cáncer de mama y analizar su implicación en la supervivencia libre de enfermedad. Material y métodos. Se incluyeron 205 pacientes con cáncer de mama tratadas con quimioterapia neoadyuvante. Se valoró la respuesta radiológica con RM pre y posquimioterapia. La respuesta patológica se clasificó según la escala de Miller y Payne. Se valoró la respuesta radiológica y patológica en cada subtipo (HER2+, TN, luminal A, luminal B HER2- y luminal B HER2+), la correlación radiopatológica y la supervivencia libre de enfermedad mediante las pruebas χ2, t de Student, ANOVA y Tau-b de Kendall. Resultados. Los subtipos HER2+ (62,1%) y TN (45,2%) mostraron mayor tasa de respuesta radiológica completa. La respuesta patológica fue del 65,5% en el HER2+, 38,1% en el TN, 2,6% en los luminales A, 8,2% en los luminales B HER2- y 31% en los luminales B HER2+. El índice de correlación radiopatológico fue significativo en todos los subtipos, mayor en los TN y HER2 (coeficientes Tau-b 0,805 y 0,717 respectivamente). La supervivencia libre de enfermedad fue mayor para HER2+ (91,9 ± 3,3 meses) y menor en el TN (69,5 ± 6,3 meses), con diferencias significativas entre los casos de mala y buena respuesta radiológica (p = 0,040). La supervivencia fue superior en los casos de buena respuesta radiológica a excepción del subtipo luminal A. Conclusión. La RM puede ser una herramienta que aporta información de la evolución del CM tratado con neoadyuvancia, variable según el subtipo inmunohistoquímico (AU)

Objectives. To evaluate the radiologic and pathologic responses to neoadjuvant chemotherapy and their correlation in the molecular subtypes of breast cancer and to analyze their impact in disease-free survival. Material and methods. We included 205 patients with breast cancer treated with neoadjuvant chemotherapy. We evaluated the radiologic response by comparing MRI images acquired before and after chemotherapy. The pathologic response was classified on the Miller and Payne scale. For each subtype (HER2+, TN, luminal A, luminal B HER2-, and luminal B HER2+), we used the χ2 test, Student's t-test, ANOVA, and Kendall's Tau-b to evaluate the radiologic response and the pathologic response, the radiologic-pathologic correlation, and the disease-free survival. Results. The subtypes HER2+ (62.1%) and TN (45.2%) had higher rates of complete radiologic response. The pathologic response was 65.5% in the HER2+ subtype, 38.1% in the TN subtype, 2.6% in the luminal A subtype, 8.2% in the luminal B HER2- subtype, and 31% in the luminal B HER2+ subtype. The rate of radiologic-pathologic correlation was significant in all subtypes, higher in TN and HER2 (Tau-b coefficients 0.805 and 0.717, respectively). Disease-free survival was higher in HER2+ (91.9 ± 3.3 months) and lower in TN (69.5 ± 6.3 months), with significant differences between the cases with poor and good radiologic responses (P=.040). Survival was greater in cases with good radiologic response, except in cases with luminal A subtype. Conclusion. MRI can be a useful tool that provides information about the evolution of breast cancer treated with neoadjuvant chemotherapy, which varies with the immunohistochemical subtype (AU)

Magnetic resonance imaging in breast cancer treated with neoadjuvant chemotherapy: radiologic-pathologic correlation of the response and disease-free survival depending on molecular subtype.

OBJECTIVES: To evaluate the radiologic and pathologic responses to neoadjuvant chemotherapy and their correlation in the molecular subtypes of breast cancer and to analyze their impact in disease-free survival. MATERIAL AND METHODS: We included 205 patients with breast cancer treated with neoadjuvant chemotherapy. We evaluated the radiologic response by comparing MRI images acquired before and after chemotherapy. The pathologic response was classified on the Miller and Payne scale. For each subtype (HER2+, TN, luminal A, luminal B HER2-, and luminal B HER2+), we used the χ(2) test, Student's t-test, ANOVA, and Kendall's Tau-b to evaluate the radiologic response and the pathologic response, the radiologic-pathologic correlation, and the disease-free survival. RESULTS: The subtypes HER2+ (62.1%) and TN (45.2%) had higher rates of complete radiologic response. The pathologic response was 65.5% in the HER2+ subtype, 38.1% in the TN subtype, 2.6% in the luminal A subtype, 8.2% in the luminal B HER2- subtype, and 31% in the luminal B HER2+ subtype. The rate of radiologic-pathologic correlation was significant in all subtypes, higher in TN and HER2 (Tau-b coefficients 0.805 and 0.717, respectively). Disease-free survival was higher in HER2+ (91.9±3.3 months) and lower in TN (69.5±6.3 months), with significant differences between the cases with poor and good radiologic responses (P=.040). Survival was greater in cases with good radiologic response, except in cases with luminal A subtype. CONCLUSION: MRI can be a useful tool that provides information about the evolution of breast cancer treated with neoadjuvant chemotherapy, which varies with the immunohistochemical subtype.

Tratamiento híbrido de un aneurisma sintomático de un divertículo de Kommerell / Hybrid treatment of a symptomatic aneurysm of a Kommerell's diverticulum

El arco aórtico izquierdo con arteria subclavia derecha aberrante constituye la anomalía vascular congénita más común del arco aórtico. En el 60% de casos se origina de un segmento dilatado, denominado divertículo de Kommerell. El aneurisma de la arteria subclavia derecha aberrante es raro, puede ser clínicamente silente o cursar con síntomas inespecíficos y su rotura se asocia a una elevada mortalidad. No hay criterios precisos para el tratamiento, pero se recomienda su reparación cuando se producen síntomas por compresión o cuando alcanza 30-50mm. La radiografía puede hacer sospechar la malformación, pero la resonancia magnética (RM) o la tomografía computarizada (TC) son las pruebas de elección para realizar el diagnóstico y planificar el tratamiento. Presentamos un caso de una arteria subclavia derecha aberrante con un pequeño aneurisma calcificado en un divertículo de Kommerell que provocó dolor torácico y disfagia y fue tratado mediante un procedimiento combinado endovascular y quirúrgico (AU)

Left aortic arch with aberrant right subclavian artery is the most common congenital vascular anomaly involving the aortic arch. In 60% of cases, the aberrant right subclavian artery arises from a dilated segment of the aortic arch called Kommerell's diverticulum. Aneurysm of the aberrant right subclavian artery is rare; this condition could remain clinically silent or it could originate nonspecific symptoms. Rupture of an aneurysm of the aberrant right subclavian artery is associated with high mortality. Although there are no exact criteria to indicate the treatment of this condition, repair of the aneurysm is recommended when symptoms occur or when it reaches a size of 30mm to 50mm. The malformation can be suspected at plain-film X-ray examination, but magnetic resonance imaging (MRI) or computed tomography (CT) are the imaging tests of choice for the diagnosis and for planning treatment. We present the case of a patient with an aberrant right subclavian artery with a small calcified aneurysm in a Kommerell's diverticulum that caused chest pain and dysphagia; the patient underwent a procedure combining endovascular and surgical treatment (AU)

[Hybrid treatment of a symptomatic aneurysm of a Kommerell's diverticulum]. / Tratamiento híbrido de un aneurisma sintomático de un divertículo de Kommerell.

Left aortic arch with aberrant right subclavian artery is the most common congenital vascular anomaly involving the aortic arch. In 60% of cases, the aberrant right subclavian artery arises from a dilated segment of the aortic arch called Kommerell's diverticulum. Aneurysm of the aberrant right subclavian artery is rare; this condition could remain clinically silent or it could originate nonspecific symptoms. Rupture of an aneurysm of the aberrant right subclavian artery is associated with high mortality. Although there are no exact criteria to indicate the treatment of this condition, repair of the aneurysm is recommended when symptoms occur or when it reaches a size of 30 mm to 50mm. The malformation can be suspected at plain-film X-ray examination, but magnetic resonance imaging (MRI) or computed tomography (CT) are the imaging tests of choice for the diagnosis and for planning treatment. We present the case of a patient with an aberrant right subclavian artery with a small calcified aneurysm in a Kommerell's diverticulum that caused chest pain and dysphagia; the patient underwent a procedure combining endovascular and surgical treatment.